|
GB9200420D0
(en)
|
1992-01-09 |
1992-02-26 |
James Black Foundation The Lim |
Amino acid derivatives
|
|
NZ249202A
(en)
|
1992-02-20 |
1996-06-25 |
Black James Foundation |
Bicyclo[2.2.2.]octane derivatives, preparation and pharmaceutical compositions thereof
|
|
JPH08508743A
(ja)
|
1993-04-15 |
1996-09-17 |
グラクソ、ウェルカム、インコーポレーテッド |
Ｃｃｋおよび／またはガストリン拮抗作用を有する１，５−ベンゾジアゼピン誘導体
|
|
ES2293638T3
(es)
|
1994-03-25 |
2008-03-16 |
Isotechnika, Inc. |
Mejora de la eficacia de farmacos por deuteracion.
|
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
|
RU2152939C1
(ru)
|
1994-04-14 |
2000-07-20 |
Глаксо Веллкам Инк. |
5-гетероцикло-1,5-бензодиазепины и их фармацевтически приемлемые соли
|
|
JPH09511998A
(ja)
|
1994-04-15 |
1997-12-02 |
グラクソ、ウェルカム、インコーポレーテッド |
１，４ − ベンゾジアゼピン化合物を用いたコレシストキニンアゴニスト活性の誘導方法
|
|
PE27497A1
(es)
|
1994-04-15 |
1997-08-07 |
Glaxo Inc |
Derivados de 1,5 benzodiazepina
|
|
FR2723739B1
(fr)
|
1994-08-19 |
1997-02-14 |
Sanofi Sa |
Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
|
|
GB9420763D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
Acetamide derivatives
|
|
GB9420747D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
1,5 benzodiazepine derivatives
|
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
EP1231219B1
(en)
|
1996-04-12 |
2010-08-25 |
1149336 Ontario Inc. |
GLucagon-like peptide-2 analogs
|
|
FR2763337B1
(fr)
|
1997-05-13 |
1999-08-20 |
Sanofi Sa |
Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
CO4970713A1
(es)
|
1997-09-19 |
2000-11-07 |
Sanofi Synthelabo |
Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
|
|
AR022044A1
(es)
|
1999-05-06 |
2002-09-04 |
Glaxo Group Ltd |
Derivados de 1,5-benzodiazepina
|
|
EP1335914A1
(en)
|
2000-10-26 |
2003-08-20 |
Sanofi-Synthelabo |
Triazole derivatives and pharmaceutical compositions comprising them
|
|
HUP0004741A2
(hu)
|
2000-11-28 |
2002-12-28 |
Sanofi-Synthelabo |
Kémiai eljárás tiazolszármazékok előállítására és új intermedier
|
|
DK1360202T3
(da)
|
2001-02-16 |
2008-09-22 |
Conjuchem Biotechnologies Inc |
Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
|
|
EP1369698A1
(en)
|
2002-06-07 |
2003-12-10 |
Bayer Ag |
Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (SSTR5)
|
|
AR043057A1
(es)
*
|
2002-10-30 |
2005-07-13 |
Vertex Pharma |
Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa
|
|
WO2005035793A2
(en)
|
2003-10-09 |
2005-04-21 |
Decode Genetics Ehf. |
Cckar markers and haplotypes associated with extreme weight conditions
|
|
US7834013B2
(en)
|
2003-11-19 |
2010-11-16 |
Glaxosmithkline Llc |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
|
|
US7517910B2
(en)
|
2004-03-30 |
2009-04-14 |
Takeda Pharmaceutical Company Limited |
Alkoxyphenylpropanoic acid derivatives
|
|
AP2006003768A0
(en)
|
2004-05-25 |
2006-10-31 |
Pfizer Prod Inc |
TetraazabenzoÄeÜazulene derivatives and analogs tehereof
|
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
|
US20080090865A1
(en)
|
2005-01-28 |
2008-04-17 |
Min Ge |
Antidiabetic Bicyclic Compounds
|
|
EP1846379B1
(en)
|
2005-01-31 |
2009-08-19 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
|
US20060177438A1
(en)
|
2005-02-08 |
2006-08-10 |
New England Medical Center |
Methods of altering absorption of hydrophobic compounds
|
|
UA95235C2
(en)
|
2005-05-04 |
2011-07-25 |
Зииланд Фарма А/С |
Glucagon-like-peptide-2 (glp-2) analogues
|
|
ES2330788T3
(es)
|
2005-06-02 |
2009-12-15 |
F. Hoffmann-La Roche Ag |
Derivados de piperidin-4-il-amida y su uso como antagonistas del subtipo 5 del receptor sst.
|
|
EA200801174A1
(ru)
|
2005-10-24 |
2009-02-27 |
Сентокор, Инк. |
Антитела-миметики glp-2, полипептиды, композиции, способы и применения
|
|
JP5075641B2
(ja)
|
2006-01-31 |
2012-11-21 |
武田薬品工業株式会社 |
遺伝子改変動物およびその用途
|
|
CN101466698A
(zh)
|
2006-04-14 |
2009-06-24 |
默克公司 |
作为缩胆囊素-1受体调节剂的取代的咪唑4-甲酰胺类化合物
|
|
ATE479435T1
(de)
|
2006-04-14 |
2010-09-15 |
Merck Sharp & Dohme |
Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
|
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
|
EP2021327B1
(en)
|
2006-05-15 |
2012-04-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
JP5290177B2
(ja)
|
2006-08-31 |
2013-09-18 |
セントカー・インコーポレーテツド |
Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
|
|
WO2008063768A2
(en)
|
2006-10-12 |
2008-05-29 |
Case Western Reserve University |
Compositions and methods for treating metabolic diseases
|
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
|
WO2008054675A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
|
CN101573376B
(zh)
|
2006-11-08 |
2013-11-06 |
西兰制药公司 |
选择性胰高血糖素样肽-2（glp-2）类似物
|
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
|
AU2007325315A1
(en)
|
2006-11-28 |
2008-06-05 |
Kalypsys Inc |
Heterocyclic modulators of TGR5
|
|
WO2008067219A2
(en)
|
2006-11-29 |
2008-06-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
AU2008209566C1
(en)
|
2007-01-19 |
2013-02-14 |
Intercept Pharmaceuticals, Inc. |
23-substituted bile acids as TGR5 modulators and methods of use thereof
|
|
CA2676222A1
(en)
|
2007-01-26 |
2008-07-31 |
Merck & Co., Inc. |
Substituted aminopyrimidines as cholecystokinin-1 receptor modulators
|
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
WO2009026241A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
WO2009034388A1
(en)
|
2007-09-10 |
2009-03-19 |
Prosidion Limited |
Compounds for the treatment of metabolic disorders
|
|
BRPI0817211A2
(pt)
|
2007-09-20 |
2017-05-16 |
Irm Llc |
composto composições como moduladores da atividade de gpr119
|
|
MY149648A
(en)
|
2007-09-21 |
2013-09-30 |
Sanofi Aventis |
Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
|
|
CN101796018A
(zh)
|
2007-09-21 |
2010-08-04 |
塞诺菲-安万特股份有限公司 |
(环丙基苯基)苯基草酰胺类化合物、其生产方法以及作为药物的用途
|
|
PT2216340E
(pt)
|
2007-10-17 |
2013-03-18 |
Univ Cordoba |
Isoformas do receptor de tipo 5 de somatostatina humana produzidas por processamento alternativo e pares oligonucleotídicos para a sua detecção por pcr
|
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
|
EP2206707B1
(en)
|
2007-10-24 |
2014-07-23 |
Astellas Pharma Inc. |
Azolecarboxamide compound or salt thereof
|
|
TW200932219A
(en)
|
2007-10-24 |
2009-08-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
|
BRPI0818687A2
(pt)
|
2007-10-26 |
2017-05-02 |
Japan Tobacco Inc |
composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
|
|
EP2215068B1
(en)
|
2007-10-29 |
2012-06-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2009106565A1
(en)
*
|
2008-02-27 |
2009-09-03 |
Biovitrum Ab (Publ) |
Agonists of gpr119
|
|
JP5665160B2
(ja)
|
2008-03-26 |
2015-02-04 |
パナソニックＩｐマネジメント株式会社 |
発光装置および照明器具
|
|
EP2271619A1
(en)
|
2008-04-07 |
2011-01-12 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
GB0812648D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
|
AU2009269772A1
(en)
*
|
2008-07-10 |
2010-01-14 |
Prosidion Limited |
Piperidinyl GPCR agonists
|
|
WO2010014739A2
(en)
|
2008-07-29 |
2010-02-04 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
EA020310B1
(ru)
|
2008-07-30 |
2014-10-30 |
Интерсепт Фармасьютикалз, Инк. |
Модуляторы рецептора tgr5 и их применение
|
|
WO2010016846A1
(en)
|
2008-08-08 |
2010-02-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
US20110171164A1
(en)
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
|
EP2358200A4
(en)
|
2008-11-17 |
2012-05-16 |
Merck Sharp & Dohme |
SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES
|
|
ES2663948T3
(es)
|
2008-11-19 |
2018-04-17 |
Intercept Pharmaceuticals, Inc. |
Moduladores de TGR5 y método de uso de los mismos
|
|
CN102282157B
(zh)
|
2008-11-19 |
2017-02-22 |
英特塞普特医药品公司 |
G蛋白偶联受体5(tgr5)调节剂及其使用方法
|
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
|
EP2389369A1
(en)
|
2009-01-23 |
2011-11-30 |
Schering Corporation |
Pentafluorosulpholane-containing antidiabetic compounds
|
|
JP2012515782A
(ja)
|
2009-01-23 |
2012-07-12 |
シェーリング コーポレイション |
抗糖尿病性架橋および縮合化合物
|
|
WO2010085525A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Bridged and fused heterocyclic antidiabetic compounds
|
|
AR075051A1
(es)
|
2009-02-05 |
2011-03-02 |
Schering Corp |
Compuestos antidiabeticos que contienen ftalazina
|
|
AR075255A1
(es)
|
2009-02-12 |
2011-03-16 |
Exelixis Inc |
Derivados diazolicos y/o triazolicos agonistas de receptores tgr5 acoplado a proteina g, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad, diabetes y otros trastornos metabolicos.
|
|
EP2399914A4
(en)
|
2009-02-18 |
2012-08-29 |
Takeda Pharmaceutical |
FUSED HETEROCYCLIC CORE COMPOUND
|
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
|
CN102421739A
(zh)
|
2009-04-22 |
2012-04-18 |
安斯泰来制药株式会社 |
羧酸化合物
|
|
WO2010143733A1
(en)
|
2009-06-09 |
2010-12-16 |
Takeda Pharmaceutical Company Limited |
Novel fused cyclic compound and use thereof
|
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
|
EP2314616A1
(en)
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
|
AU2010312365A1
(en)
|
2009-10-30 |
2012-06-07 |
Mochida Pharmaceutical Co.,Ltd. |
Novel 3-hydroxy-5-arylisoxazole derivative
|
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
|
CN102781922A
(zh)
|
2009-12-11 |
2012-11-14 |
埃克塞利希斯股份有限公司 |
Tgr5激动剂
|
|
CN104710381A
(zh)
|
2009-12-25 |
2015-06-17 |
持田制药株式会社 |
新的3-羟基-5-芳基异噻唑衍生物
|
|
AU2011256444B2
(en)
|
2010-05-18 |
2014-07-10 |
Merck Sharp & Dohme Corp. |
Spiro isoxazoline compounds as SSTR5 antagonists
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
RU2627703C2
(ru)
|
2010-07-23 |
2017-08-10 |
Конекшис Лайф Сайенсиз Пвт. Лтд. |
Агонисты gpr40
|
|
WO2012024183A1
(en)
|
2010-08-18 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
|
JP5908478B2
(ja)
|
2010-08-30 |
2016-04-26 |
エヌピーエス ファーマシューティカルズ インコーポレイテッドＮｐｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
|
|
JP5809157B2
(ja)
|
2010-10-08 |
2015-11-10 |
持田製薬株式会社 |
環状アミド誘導体
|
|
WO2012070554A1
(ja)
|
2010-11-22 |
2012-05-31 |
国立大学法人京都大学 |
ペプチド
|
|
DK2646425T3
(en)
|
2010-12-01 |
2015-08-24 |
Boehringer Ingelheim Int |
Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome.
|
|
WO2012082947A1
(en)
|
2010-12-16 |
2012-06-21 |
Irm Llc |
Compounds and compositions as tgr5 agonists
|
|
JP5945545B2
(ja)
|
2011-02-17 |
2016-07-05 |
武田薬品工業株式会社 |
光学活性なジヒドロベンゾフラン誘導体の製造法
|
|
US8957062B2
(en)
*
|
2011-04-08 |
2015-02-17 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
|
EP2694092B1
(en)
|
2011-04-08 |
2017-01-04 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
|
RU2013152631A
(ru)
|
2011-04-27 |
2015-06-10 |
Мотида Фармасьютикал Ко., Лтд. |
Новое 3-гидроксиизотиазол-1-окидное производное
|
|
WO2012149236A1
(en)
|
2011-04-28 |
2012-11-01 |
Bristol-Myers Squibb Company |
Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators
|
|
EP2720544B1
(en)
*
|
2011-06-16 |
2016-12-21 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
|
WO2013054338A1
(en)
|
2011-07-06 |
2013-04-18 |
Cadila Healthcare Limited |
2-thio-imidazole derivatives as tgr5 modulators
|
|
TWI537262B
(zh)
|
2011-08-17 |
2016-06-11 |
美國禮來大藥廠 |
供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
|
|
JP6206972B2
(ja)
|
2011-09-12 |
2017-10-04 |
アムニクス オペレーティング インコーポレイテッド |
グルカゴン様ペプチド−２組成物およびその作製法および使用法
|
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
|
WO2013074388A1
(en)
*
|
2011-11-15 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
|
CA2859965A1
(en)
|
2011-12-21 |
2013-06-27 |
Ardelyx, Inc. |
Non-systemic tgr5 agonists
|
|
CN103429581B
(zh)
|
2012-01-12 |
2015-08-26 |
江苏恒瑞医药股份有限公司 |
多环类衍生物、其制备方法及其在医药上的应用
|
|
GB2498976A
(en)
*
|
2012-02-01 |
2013-08-07 |
Prosidion Ltd |
GPR119 agonists useful in the treatment of type II diabetes
|
|
JP6121339B2
(ja)
|
2012-02-13 |
2017-04-26 |
武田薬品工業株式会社 |
芳香環化合物
|
|
WO2013122028A1
(ja)
|
2012-02-13 |
2013-08-22 |
武田薬品工業株式会社 |
芳香環化合物
|
|
KR20140138243A
(ko)
|
2012-02-28 |
2014-12-03 |
피라말 엔터프라이지즈 리미티드 |
G 단백질 연결 수용체 작용물질로서의 페닐알칸산 유도체
|
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規５－アリール－１，２－チアジナン誘導体
|
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
|
CN104540850B
(zh)
|
2012-05-03 |
2018-05-18 |
西兰制药公司 |
胰高血糖素样肽2(glp-2)类似物
|
|
US8633182B2
(en)
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2014052379A1
(en)
*
|
2012-09-26 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds
|
|
AU2013334122B2
(en)
|
2012-10-26 |
2017-11-02 |
Intercept Pharmaceuticals, Inc. |
Process for preparing bile acid derivatives
|
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Ｌｇ化學股份有限公司 |
Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
|
SG11201503697TA
(en)
|
2012-11-28 |
2015-06-29 |
Intercept Pharmaceuticals Inc |
Treatment of pulmonary disease
|
|
EP2925748B1
(en)
|
2012-11-28 |
2017-01-11 |
Boehringer Ingelheim International GmbH |
Indanyloxydihydrobenzofuranylacetic acids as modulators of the g-protein coupled receptor 40 (gpr40) and of the free fatty acid receptor 1 (ffar1) for the treatment of metabolic diseases
|
|
US20140163025A1
(en)
|
2012-12-07 |
2014-06-12 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
|
WO2014100025A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen
|
|
WO2014096440A2
(en)
|
2012-12-21 |
2014-06-26 |
Novozymes Biopharma Dk A/S |
Composition
|
|
JP6314335B2
(ja)
|
2013-02-06 |
2018-04-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新しいインダニルオキシジヒドロベンゾフラニル酢酸
|
|
KR20150118158A
(ko)
|
2013-02-22 |
2015-10-21 |
머크 샤프 앤드 돔 코포레이션 |
항당뇨병 비시클릭 화합물
|
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
|
AR096041A1
(es)
|
2013-04-17 |
2015-12-02 |
Piramal Entpr Ltd |
Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
|
|
CN104870429B
(zh)
|
2013-05-22 |
2017-05-03 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
|
CN105636984A
(zh)
|
2013-06-13 |
2016-06-01 |
法斯特弗沃德制药有限公司 |
用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物，该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
|
|
CN104507921B
(zh)
|
2013-07-02 |
2017-02-22 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
|
CN105143181B
(zh)
|
2013-07-26 |
2017-12-26 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
|
US9862752B2
(en)
|
2013-07-31 |
2018-01-09 |
Amgen Inc. |
Growth differentiation factor 15 (GDF-15) constructs
|
|
PL3031799T3
(pl)
|
2013-08-09 |
2018-09-28 |
Takeda Pharmaceutical Company Limited |
Związek aromatyczny
|
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
|
CN105473595A
(zh)
|
2013-08-23 |
2016-04-06 |
福建海西新药创制有限公司 |
治疗糖尿病的羧酸化合物
|
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
|
CN105246875A
(zh)
|
2013-09-03 |
2016-01-13 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
|
EP3049396B1
(en)
|
2013-09-26 |
2017-11-15 |
Boehringer Ingelheim International GmbH |
Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
|
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
CN104592211B
(zh)
|
2013-10-31 |
2018-10-16 |
广东东阳光药业有限公司 |
联苯类化合物及其用途
|
|
EP3068788A1
(en)
|
2013-11-14 |
2016-09-21 |
Cadila Healthcare Limited |
Novel heterocyclic compounds
|
|
EP3068768B1
(en)
|
2013-11-15 |
2019-07-31 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
EP3074375B1
(en)
|
2013-11-28 |
2018-04-04 |
Boehringer Ingelheim International GmbH |
New indanyloxyphenylcyclopropanecarboxylic acids
|
|
EP3076959B1
(en)
|
2013-12-04 |
2018-07-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎三唑并吡啶化合物
|
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
|
JP6170255B2
(ja)
|
2014-01-10 |
2017-07-26 |
イーライ リリー アンド カンパニー |
イソプロピルトリアゾロピリジン化合物
|
|
KR20160095117A
(ko)
|
2014-01-10 |
2016-08-10 |
일라이 릴리 앤드 캄파니 |
페닐-트리아졸로-피리딘 화합물
|
|
WO2015119899A1
(en)
|
2014-02-06 |
2015-08-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
|
WO2015160772A1
(en)
|
2014-04-15 |
2015-10-22 |
Janssen Pharmaceutica Nv |
Tetrahydro-benzoimidazolyl modulators of tgr5
|
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2015183794A1
(en)
|
2014-05-27 |
2015-12-03 |
City Of Hope |
Tgr5 agonist complexes for treating diabetes and cancer
|
|
US10407462B2
(en)
|
2014-05-29 |
2019-09-10 |
Bar Pharmaceuticals S.R.L. |
Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
|
|
EP3157947A1
(en)
|
2014-06-23 |
2017-04-26 |
Novartis AG |
Hsa-gdf-15 fusion polypeptide and use thereof
|
|
EP3164538A1
(en)
|
2014-07-02 |
2017-05-10 |
Arçelik Anonim Sirketi |
Built-in household appliance unpowered control and status indication device
|
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
WO2016022742A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
WO2016022446A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
|
WO2016054208A1
(en)
|
2014-10-03 |
2016-04-07 |
Mayo Foundation For Medical Education And Research |
Targeting tgr5 to treat disease
|
|
TW201629033A
(zh)
|
2014-10-08 |
2016-08-16 |
健生藥品公司 |
作為治療第二型糖尿病之ｇｐｒ４０促效劑的經取代苯并噻吩基衍生物
|
|
KR101726819B1
(ko)
*
|
2014-10-27 |
2017-04-13 |
동아에스티 주식회사 |
Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
|
|
US20180280480A1
(en)
|
2014-10-31 |
2018-10-04 |
Gubra Aps |
Compositions and peptides having dual glp-1r and glp-2r agonist activity
|
|
WO2016073767A1
(en)
|
2014-11-06 |
2016-05-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
|
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
|
MX2017010376A
(es)
|
2015-02-11 |
2017-12-20 |
Enanta Pharm Inc |
Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
|
|
CA2981503C
(en)
|
2015-03-31 |
2023-09-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
TW201712012A
(zh)
|
2015-06-16 |
2017-04-01 |
美國禮來大藥廠 |
２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
|
|
EP3310801B1
(en)
|
2015-06-19 |
2021-04-07 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
|
JP6772133B2
(ja)
|
2015-07-02 |
2020-10-21 |
サントリーホールディングス株式会社 |
Ｇｌｐ−２分泌促進用組成物
|
|
WO2017005765A1
(en)
|
2015-07-06 |
2017-01-12 |
Novo Nordisk A/S |
Novel peptides and peptide derivatives and uses thereof
|
|
CN108137643A
(zh)
|
2015-08-07 |
2018-06-08 |
英特塞普特医药品公司 |
制备胆汁酸及其衍生物的方法
|
|
JP6816107B2
(ja)
|
2015-08-07 |
2021-01-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用
|
|
WO2017027312A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
|
WO2017027310A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
|
WO2017027309A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
|
EP3347358B1
(en)
|
2015-09-09 |
2019-11-27 |
Boehringer Ingelheim International GmbH |
[{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
|
|
EP3353189A4
(en)
|
2015-09-24 |
2019-06-19 |
Intercept Pharmaceuticals, Inc. |
METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF GALLENIC ACID DERIVATIVES
|
|
MX2018005520A
(es)
|
2015-11-06 |
2018-08-01 |
Intercept Pharmaceuticals Inc |
Metodos para preparacion de acido obeticolico y derivados de los mismos.
|
|
TWI773657B
(zh)
|
2015-12-18 |
2022-08-11 |
美商亞德利克斯公司 |
作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
|
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
US10323060B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
|
|
CN108697795A
(zh)
|
2016-02-29 |
2018-10-23 |
伊莱利利公司 |
Gfral受体疗法
|
|
US10676458B2
(en)
|
2016-03-29 |
2020-06-09 |
Merch Sharp & Dohne Corp. Rahway |
Antidiabetic bicyclic compounds
|
|
US10106553B2
(en)
|
2016-04-11 |
2018-10-23 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
|
|
WO2017180577A1
(en)
|
2016-04-13 |
2017-10-19 |
Intercept Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
WO2018005794A2
(en)
|
2016-07-01 |
2018-01-04 |
Venenum Biodesign Llc |
Novel non-systemic tgr5 agonists
|
|
WO2018005801A2
(en)
|
2016-07-01 |
2018-01-04 |
Venenum Biodesign Llc |
Novel non-systemic tgr5 agonists
|
|
WO2018009778A1
(en)
|
2016-07-07 |
2018-01-11 |
Baylor College Of Medicine |
Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
|
|
CA3038534A1
(en)
|
2016-09-30 |
2018-04-05 |
Intercept Pharmaceuticals, Inc. |
Crystalline forms of a bile acid derivative
|
|
KR20190059312A
(ko)
|
2016-10-12 |
2019-05-30 |
얀센 바이오테크 인코포레이티드 |
Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법
|
|
WO2018081047A1
(en)
|
2016-10-25 |
2018-05-03 |
Janssen Pharmaceutica Nv |
Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
|
|
WO2018077699A1
(en)
|
2016-10-25 |
2018-05-03 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
JP7008704B2
(ja)
|
2016-11-28 |
2022-01-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
CA3044915A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
EP3551651B1
(en)
|
2016-12-09 |
2024-03-06 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
|
EP3558298B1
(en)
|
2016-12-20 |
2026-03-11 |
Merck Sharp & Dohme LLC |
Antidiabetic spirochroman compounds
|
|
JP6968181B2
(ja)
|
2017-01-26 |
2021-11-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
|
|
US10919859B2
(en)
|
2017-01-26 |
2021-02-16 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
CN110198928B
(zh)
|
2017-01-26 |
2023-08-29 |
勃林格殷格翰国际有限公司 |
苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
|
|
WO2018138030A1
(en)
|
2017-01-26 |
2018-08-02 |
Boehringer Ingelheim International Gmbh |
Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
US10793530B2
(en)
|
2017-01-26 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
WO2018142363A1
(en)
|
2017-02-06 |
2018-08-09 |
Orbicular Pharmaceutical Technologies Private Limited |
Ready to use compositions of glp-2 analogues through self-administrable devices
|
|
JP7049353B2
(ja)
|
2017-02-08 |
2022-04-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
|
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
|
WO2018181847A1
(ja)
|
2017-03-31 |
2018-10-04 |
武田薬品工業株式会社 |
芳香環化合物
|
|
CN107162921B
(zh)
|
2017-05-27 |
2019-12-13 |
中国药科大学 |
一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
|
|
WO2018222701A1
(en)
|
2017-05-30 |
2018-12-06 |
Intercept Pharmaceuticals, Inc. |
Treatment of renal diseases with a bile acid derivative
|
|
WO2018226724A1
(en)
|
2017-06-05 |
2018-12-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of diabetic eye diseases with a bile acid derivatives
|
|
IL299864B2
(en)
|
2017-06-16 |
2024-06-01 |
Zealand Pharma As |
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
|
|
JP7224307B2
(ja)
|
2017-06-23 |
2023-02-17 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
胆汁酸誘導体の調製のための方法及び中間体
|
|
BR112020003736A2
(pt)
|
2017-08-22 |
2020-09-08 |
Shire-Nps Pharmaceuticals, Inc. |
polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais
|
|
WO2019086559A1
(fr)
|
2017-10-31 |
2019-05-09 |
Adocia |
Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
WO2019090209A1
(en)
|
2017-11-06 |
2019-05-09 |
Shire-Nps Pharmaceuticals, Inc. |
Glp-2 analogs and peptibodies for administration before during, or after surgery
|
|
US11225471B2
(en)
|
2017-11-16 |
2022-01-18 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
US11964938B2
(en)
|
2018-01-08 |
2024-04-23 |
Celon Pharma S.A. |
3-phenyl-4-hexynoic acid derivatives as GPR40 agonists
|
|
US20220152164A1
(en)
|
2019-03-22 |
2022-05-19 |
Kallyope, Inc. |
Gpcr combination therapies
|
|
US20220226298A1
(en)
|
2019-05-29 |
2022-07-21 |
Kallyope, Inc. |
Gpr40 agonists
|
|
KR20220150270A
(ko)
|
2019-10-07 |
2022-11-10 |
칼리오페, 인크. |
Gpr119 효능제
|
|
WO2021113363A1
(en)
|
2019-12-03 |
2021-06-10 |
Kallyope, Inc. |
Sstr5 antagonists
|
|
TW202140440A
(zh)
|
2020-02-28 |
2021-11-01 |
美商克力歐普股份有限公司 |
Gpr40激動劑
|
|
WO2021174046A1
(en)
|
2020-02-28 |
2021-09-02 |
Kallyope, Inc. |
Gpr40 agonists
|